
Medication Interaction & Safety Assessment for Complex Cases
Assess drug interactions and safety for complex polypharmacy cases
What You Can Do
You can conduct comprehensive medication safety reviews for complex polypharmacy cases by analyzing drug-drug interactions within the context of each patient's clinical scenario—renal function, hepatic metabolism, age, and comorbidities. The skill distinguishes between theoretical concerns and actionable safety issues, quantifies clinical risk, and generates specific intervention recommendations with documented reasoning for provider communication.
Features
categorizes interactions by clinical significance (major, moderate, minor) based on patient-specific factors like renal/hepatic function
identifies absolute contraindications and relative cautions within each patient's disease state and organ function profile
calculates necessary dose modifications for renal impairment, hepatic dysfunction, and drug-drug interactions with evidence-based rationale
maps shared cytochrome P450 pathways and transporter interactions to predict accumulation and toxicity risks
prioritizes monitoring for drugs with limited therapeutic windows (warfarin, digoxin, phenytoin, lithium)
identifies redundant or interacting medications as candidates for discontinuation based on clinical benefit vs. risk
structures interaction summary, risk assessment, and recommendations in provider-ready format for MTM or clinical consultation
incorporates age, renal function (GFR), hepatic status, and comorbidities to distinguish theoretical from actionable concerns
Example Output
Case: 78-year-old with CKD Stage 3b (GFR 35) on Warfarin, Amiodarone, ACE-I, Metformin, Atorvastatin
Risk Summary:
- MAJOR: Warfarin + Amiodarone → increased INR, bleeding risk (CYP3A4 inhibition)
- MAJOR: Metformin + Stage 3b CKD → lactic acidosis risk; recommend dose reduction
- MODERATE: Atorvastatin + Amiodarone → statin myopathy risk; monitor CK, consider pravastatin
Recommendations:
- Reduce metformin from 1000mg daily to 500mg daily; recheck eGFR in 3 months
- Monitor INR weekly × 4 weeks after amiodarone initiation; target INR 2-3
- Consider pravastatin 10mg daily (minimal CYP3A4 metabolism) instead of atorvastatin
- Counsel on amiodarone-warfarin interaction; educate on bleeding precautions
Monitoring Plan: INR, renal function q3mo; CK baseline then q6mo if continuing atorvastatin
What's Included
- SKILL.md: full instruction file with core workflow, assessment framework, and clinical decision logic
- Polypharmacy Assessment Template: structured form for medication inventory, patient context, interaction matrix, and risk stratification
- Interaction Priority Checklist: quick reference for major interactions, contraindications, and dose adjustments by drug class
- Clinical Documentation Framework: provider-ready summary format including risk categorization, recommendations, and monitoring parameters
- Renal/Hepatic Dosing Guide: quick-lookup table for common medications requiring adjustment by kidney/liver function
Who It's For
- Clinical pharmacists conducting medication therapy management (MTM) reviews and consultations
- Hospital pharmacists managing complex polypharmacy cases and deprescribing initiatives
- Primary care providers evaluating multi-drug regimens for safety and efficacy
- Geriatric specialists assessing medication burden in older adults on 5+ drugs
- Nephrology and hepatology clinicians optimizing dosing in renal/hepatic impairment
Best For
- Polypharmacy safety reviews for patients on ≥5 medications
- Drug interaction assessment when adding new medications to complex regimens
- Dose optimization in renal impairment (CKD Stage 3-5) and hepatic dysfunction
- Narrow therapeutic index drug monitoring (warfarin, digoxin, phenytoin, lithium)
- Deprescribing recommendations to reduce medication-related harm
- Medication therapy management (MTM) documentation for provider justification







